Mexiprim - instructions for use, doses, side effects, contraindications

Mexiprem® refers to heteroaromatic antioxidants. Has a wide range of pharmacological activity: increases the resistance of the body to stress, shows an anxiolytic effect, not accompanied by drowsiness and muscle relaxant effect; has nootropic properties, prevents and reduces learning and memory disruptions arising from aging and the effects of various pathogenic factors; has an anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases concentration and efficiency; alleviates the toxic effects of alcohol.

The drug improves the metabolism of brain tissues and their blood supply, improves microcirculation and rheological properties of blood, reduces the aggregation of platelets. Stabilizes the membrane structures of blood cells (erythrocytes and platelets).Has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins.

Mechanism of action Mexicopa® is due to its antioxidant and membrane protective action. is he inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid-protein, reduces the viscosity of the membrane, increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structurally functional organization of biomembranes, the transport of neurotransmitters and the improvement of synaptic transmission. Mexiprim® increases the content of dopamine in the brain. It causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

Pharmacokinetics:

The maximum concentration of Mexicum ® in the blood plasma is in the range of 50 to 100 ng / ml.

The half-life of Mexuprem® and the average retention time in the body are 4.7-5 hours and 4.9-5.2 hours, respectively. Mexiprem ® in the human body is intensively metabolized with the formation of its glucuronoconjugated product. On average, for 12 hours with urine excreted 0.3% unchanged drug and 50% in the form of glucuronoconjugate from the administered dose. Most intensively, Mexiprim® and its glucuronoconjugate are excreted within the first 4 hours after taking the drug. The urinary excretion of Mexiprim® and its conjugated metabolite have significant individual variability.

Indications:

- Acute disorders of cerebral circulation (as part of complex therapy);

- encephalopathy;

- vegetative-vascular dystonia;

- anxiety states in neurotic and neurosis-like states;

- light cognitive disorders of different genesis (psycho-organic and asthenic syndrome, consequences of craniocerebral trauma, atherosclerosis, senile and atrophic processes, neuroinfections and intoxications);

- memory disorders and intellectual insufficiency in the elderly;

- the impact of extreme (stressor) factors;

- abstinence syndrome with alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

- acute intoxication with antipsychotic drugs.

Contraindications:

Acute hepatic and / or renal failure, increased individual sensitivity to the drug.

Children's age, pregnancy, breastfeeding - due to insufficient study of the effect of the drug in these categories of patients.

Dosing and Administration:

Mexiprim® is administered intramuscularly or intravenously (either by jet or by drip). Doses are selected individually. With an infusion method of administration, the drug should be diluted in a saline solution of sodium chloride. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose to obtain a therapeutic effect. Jet Miksiprim® is injected slowly for 5-7 minutes, drip - at a speed of 40-60 drops per minute. The maximum daily dose does not exceed 800 mg.

In acute disorders of cerebral circulation Mexiprem ® is used in complex therapy in the first 2-4 days intravenously drip 200-300 mg once a day, then intramuscularly 100 mg 3 times a day. The duration of treatment is 10-14 days.

With discirculatory encephalopathy in the phase of decompensation Mexiprem® should be administered intravenously in a stream or drip in a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg 2-3 times a day for the next 2 weeks.

For the course of prophylaxis of dyscirculatory encephalopathy the drug is administered intramuscularly at a dose of 100 mg twice a day for 10-14 days.

With mild cognitive impairment in elderly patients and with anxiety disorders the drug is used intramuscularly in a daily dose of 100-300 mg for 14-30 days.

With abstinence alcohol syndrome Mexiprim® is administered in a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days. In acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.

Side effects:

Rarely - nausea, dryness of the oral mucosa, drowsiness, allergic reactions.

Overdose:

Symptoms: violation of sleep (insomnia, in some cases - drowsiness).

Treatment: as a rule, is not required - the symptoms disappear on their own within 24 hours.

In severe cases with insomnia it is recommended to take sleeping pills.

Interaction:

Mexiprem ® is compatible with psychotropic drugs; enhances the action of benzodiazepine anxiolytics, antiparkinsonics and carbamazepine.

Reduces the toxic effect of ethyl alcohol.

Effect on the ability to drive transp. cf. and fur:

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

Solution for intravenous and intramuscular injection, 50 mg / ml.

Packaging:

In production at FSUE "Moscow Endocrine Plant", Russia

By 2 ml or 5 ml into neutral glass ampoules of grade НС-3 or imported.

5 ampoules per contour mesh package made of polyvinylchloride film or from polyvinylchloride film and aluminum foil.

For 1, 2 or 3 contour packs with instructions for medical use of the drug, a knife or ampoule scapegrip placed in a pack of cardboard.

For hospitals 6, 12, 20, 50 or 100 contour cell packs with foil with 3, 6, 10, 25 or 50 instructions for the medical use of the preparation, knives or ampoule scalers are placed in carton boxes or in corrugated cardboard boxes.

When packing ampoules with incisions, rings or break points, scarifiers or ampoule knives do not.

When produced at LLC "NTFF" POLISAN ", Russia

By 2 ml or 5 ml into neutral glass ampoules of grade НС-3 or imported, or ampoules of brown glass.

5 ampoules per contour cell packaging made of a polyvinylchloride film, or a polyvinylchloride film and aluminum foil, or a polyvinylchloride film and a cover film.

For 1, 2 or 3 contour packs with instructions for medical use of the drug, a knife or ampoule scapegrip placed in a pack of cardboard.

For hospitals by 6, 12, 20, 50 or 100 contour cell packs with a foil or cover film with 6, 12, 20, 50 or 100 instructions for the medical use of the preparation, knives or ampoule scalers, respectively, are placed in carton boxes or in boxes of corrugated cardboard.

When packing ampoules with incisions, rings or break points, scarifiers or ampoule knives do not.

Storage conditions:

In the dark place at a temperature of no higher than 20 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-001668

Date of registration:29.08.2008 / 19.11.2013

Expiration Date:Unlimited

The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia

Manufacturer: & nbsp

MOSCOW ENDOCRINE FACTORY, FSUE Russia

POLISAN NTPF, LLC Russia

Representation: & nbspNizhpharm, JSCNizhpharm, JSCRussia

Information update date: & nbsp27.04.2018

Illustrated instructions

Instructions

Mexiprem ® (Mexiprim®)